Designing a Treatment Plan From the Label: Session Counts, Interval Floors and the Touch-Up You Should Have Priced

The products in your injectable fridge already contain a treatment plan. Not a marketing plan, a dosing plan: a session count, an interval floor, a cumulative ceiling, and in one case a second appointment that was written into the pivotal trial before the product was ever sold in a clinic.

Almost no plan sold in this market is built from that. Plans get built from a menu, a package discount and a monthly revenue target, and a session count is attached afterwards. The two rules operators repeat most often do not survive a reading of the current labels. Sculptra is not a three-week product any more. BOTOX Cosmetic's label does not instruct a ninety-day floor at all.

This post rebuilds four common plans from the approved labeling, quotes the operative sentences with their document numbers and dates, and then sets out what a booking and charting system has to do to hold a plan together across sessions.

Every source on this page was read on 19 August 2026. We make med spa software, so we have an obvious interest in how treatment plans get sequenced, booked and charted. The label language below holds regardless of whose software you run it in.

A plan is a sequence with floors and ceilings, not a menu with a discount

Read the physician labeling for the multi-session products and the same four elements keep appearing: how many sessions belong in one regimen, how long you wait between them, how much product may go in per session, and how much may go in cumulatively before the manufacturer stops claiming evidence. Where a label was superseded, we say which supplement replaced it. Where a number comes from a trial rather than a dosing instruction, we say that too, because the difference changes what you are allowed to promise.

Sculptra's current Instructions for Use, approved as PMA supplement P030050/S039 on 25 April 2023, states that use "should be limited to use in a single regimen of up to four sequential sessions each spaced three to four-weeks apart." That is a session cap and an interval floor in one sentence.

The RADIESSE Injectable Implant Instructions for Use, document IN00244-00 dated March 2026 and approved under PMA P050052/S162, supplies the ceiling in its Precautions: "Injection of more than 18 mL diluted 1:2 RADIESSE Injectable Implant (6 mL of RADIESSE and 12 mL of saline solution) cumulatively over a series of 4 injections has not been studied in clinical trials."

A package priced as "four sessions for a discount" carries none of that structure. It carries a payment schedule. The structure lives in the interval between sessions, the assessment that happens before the next one is authorised, and the running total of product already delivered. If those three things are not tracked per patient, what you sold is a payment plan.

Sculptra: up to four sessions, and two different interval floors in one label

The three-week figure that circulates in operator groups is real, and it is retired. It comes from the 2009 labeling, PMA supplement P030050/S002. Two supplements have replaced it since. P030050/S034, approved 23 November 2021, changed the reconstitution and injection procedure and merged the physician labeling under the single trade name Sculptra. P030050/S039, approved 25 April 2023, added a cheek-region indication.

The current label carries two floors, not one. For nasolabial folds it instructs you to "Re-evaluate the patient no sooner than three to four weeks after the injection session" and to keep "the minimum of 3-4 weeks between assessment and possible next injection session." For the cheek region it is stricter: re-evaluate "no sooner than four weeks," with "the minimum of four weeks between assessment and possible next injection session." One product, two floors, depending on which area you treated.

The label also tells you what a session is supposed to look like, and the instruction is not limited to the first one. Section 2 states that "During the initial treatment session with Sculptra, only a limited correction should be made." Section 10, headed "Degree of Correction, Treat, Wait, Assess," goes further: "The contour deficiency should be under-corrected, never fully corrected or overcorrected (overfilled) during any injection session." Under-correction is the labeled target at every visit in the regimen, which is why the regimen exists.

Two more details in the same document change how a plan gets quoted. The clinical section of the current label is titled for reconstitution with 8 mL sterile water for injection plus 1 mL of 2% lidocaine, so protocols built on the older 5 mL reconstitution are describing a superseded procedure. And the per-session volume is capped: "a maximum of 2.5 mL in 5 mL reconstitution or 4.5 mL [in 8 mL reconstitution]" per nasolabial fold per session, while "Treatment of an entire cheek typically requires injection of one vial of Sculptra per cheek per session."

Juvederm Voluma XC: the touch-up was in the study design

The Juvederm Voluma XC Directions for Use, document L3781 Rev01, copyright 2013, approved under PMA P110033, describes the mid-face pivotal study plainly: "Up to 2 treatments approximately 1 month apart (initial treatment and up to 1 touch-up treatment) were allowed." The adverse events section adds that "Touch-up treatments occurred approximately 30 days after initial injection."

The second appointment was not an exception handled at the front desk. It was a protocol-permitted part of the treatment, designed in before the device was approved, and it was used: the same document states that "A touch-up treatment was performed for 82% (195/238) of subjects." The label does not say those subjects needed it, and clinical need was not the endpoint. The touch-up was an allowed second treatment at investigator discretion to reach optimal correction. "Performed for" is the verb the document uses, and it is the verb to repeat.

One qualification on that document. It is the original 2013 cheek-only Directions for Use. Voluma XC's indications have expanded since: PMA supplement P110033/S070, approved 6 October 2023, covers supraperiosteal injection to augment the temple region for moderate to severe temple hollowing in adults over the age of 21. The 2013 figures remain accurate statements about the 2013 mid-face trial. They are not a description of the product's full current indication set.

Radiesse in the decollete: what the label instructs, and what only the trial did

Radiesse gained a decollete indication at PMA supplement P050052/S162, a panel-track supplement received 22 May 2024 with a decision date of 31 March 2026. The approval covers Radiesse "diluted 1:2 with 0.9% sterile saline solution for subdermal implantation for the correction of decollete wrinkles in patients 22 years of age and older." That indication is roughly five months old as of publication, so anyone building a plan around it is building on new labeling.

The dilution is specified: 1.5 mL of Radiesse to 3.0 mL of saline, yielding 4.5 mL, mixed with at least twenty back-and-forth passes and injected through a 22G cannula. Section 7.2 opens with a timing caution: "Only use diluted RADIESSE Injectable Implant within 30 minutes after preparation. It is recommended to inject the diluted product immediately when feasible." That is a use window measured from preparation, not a storage life, and it is a real constraint on how you stack decollete appointments in a room.

What section 7.2 does not contain is a schedule. We read the Directions for Use for the decollete line by line on 19 August 2026: it gives dilution steps and injection technique, and states no session count, no cadence and no retreatment interval. The Day 1, Week 6 and Week 12 sequence that circulates as "the Radiesse decollete protocol" appears in section 6.3.2, Clinical Studies, as the design of the trial: subjects in the treatment group "received treatment on Day 1, Week 6, and Week 12 with optional retreatment at Week 36." That is four possible visits, not three, and it is study design rather than a dosing instruction.

Two labeled precautions in the same document are operational line items rather than clinical footnotes. Completion of an indication-specific training program "is required for all users" for the decollete indication. And the same Instructions for Use states that Merz does not offer the components for dilution and injection commercially, so the practice sources its own syringes, connector and cannula. Both belong in the cost of adding the service, alongside the note that safety beyond 84 weeks in the decollete has not been established.

The six neurotoxin labels: five instruct, one records an evidence gap

There are six botulinum toxin products with FDA-approved cosmetic indications, on the labels we read on 19 August 2026. The table below gives each one's current label version, its approved cosmetic areas, its retreatment language quoted verbatim, and its labeled cosmetic doses. Doses are shown only within a product, because every one of these labels states that its units are not interchangeable with other botulinum toxin preparations.

The interesting divergence is narrow and precise. Five of the six carry a near-identical directive. BOTOX Cosmetic alone declines to instruct, and instead records an evidence gap: dosing more frequently than every three months has not been clinically evaluated. A directive and a stated absence of evidence are different things, and a system rule that hard-blocks every toxin booking at ninety days is enforcing sentences that five of the six labels contain.

The approved areas diverge more than the intervals do. BOTOX Cosmetic has four cosmetic areas as of the 10/2024 label, including platysma bands, which is the only labeled neck indication among the six. XEOMIN has three. Dysport, Jeuveau, Daxxify and Letybo are glabellar lines only. Menus that sell "neck tox" or "forehead tox" as generic line items are describing something that maps to one product's labeling, not to whichever vial is in the drawer that morning.

Dysport also carries an eligibility boundary the other five do not. Its indication reads "in adults less than 65 years of age," where the rest read in adult patients. That is a plan-eligibility fact, not a trivia fact, and it belongs in the same place your intake collects date of birth. The same table also explains why brand substitution mid-plan is not a stock decision: units are not interchangeable across products, and the approved area may not carry over either.

Same-day combinations the labels do price, and the point where evidence stops

Combination treatment is not automatically off-label improvisation. Within a single toxin product, some combinations are labeled with their own arithmetic. BOTOX Cosmetic instructs that forehead lines be treated "in conjunction with glabellar lines" at a recommended total of 40 Units, so forehead lines alone are not a labeled treatment at all. For lateral canthal plus glabellar treated simultaneously, "the dose is 24 Units for lateral canthal lines and 20 Units for glabellar lines ... with a total dose of 44 Units." All three areas at once is a total dose of 64 Units. XEOMIN labels simultaneous glabellar and horizontal forehead treatment at 40 Units.

Across products and across modalities, the labels stop supplying answers, and they say so. Sculptra's current Instructions for Use states that "The safety and effectiveness of injecting Sculptra: 1) in larger amounts, 2) at different frequencies, 3) at anatomic sites different than specified for the intended use of the product, or 4) at anatomic sites that have had other dermal filler injections, have not been evaluated."

The Radiesse decollete trial goes one step further and removes the question by design. Its exclusion criteria ruled out subjects with "Previous treatment with botulinum toxin, ablative or fractional laser, microdermabrasion, microneedling, chemical peels, and/or non-invasive skin tightening in the decollete within the previous 6 months." A trial built that way cannot produce evidence about combining, which is worth knowing before a treatment plan sequences a laser series and a decollete series in the same quarter.

One warning appears in both biostimulator labels, word for word apart from the product name. Sculptra: "If laser treatment, chemical peeling or any other procedure based on active dermal response is considered after treatment with Sculptra, there is a possible risk of eliciting an inflammatory reaction at the implant site. This also applies if Sculptra is administered before the skin has healed completely after such a procedure." Radiesse says the same about Radiesse. Neither label states a number of days anywhere in the physician Instructions for Use we read on 19 August 2026, which means the interval your clinic uses is a clinical judgment your notes should record, not a setting anyone can hand you.

Pricing the plan from the median course, not the first appointment

The table below sets each multi-session plan next to what its own document actually states, separating instructions from study design.

The pricing argument is in the Voluma numbers, and it comes from the manufacturer's own document rather than from anyone's practice data. Treatment Characteristics in the 2013 Directions for Use states that "The overall total volume used to achieve optimal correction for all 3 sub-regions ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL. The median volume at initial treatment was 4.8 mL ... The median total volume used for touch-up treatment was 1.9 mL."

Read those three figures together. The median course consumed 6.6 mL. The median first appointment consumed 4.8 mL. A quote built on the first appointment describes roughly 1.8 mL less product than the median subject received on the way to optimal correction. Note also what the document withholds: it says only that "The volume in each syringe is as stated on the syringe label," so there is no way to convert those millilitres into a syringe count from this source.

The same pattern shows up in completion behaviour. In the Radiesse decollete study, 60.7% (65 of 107) of the treatment group received all three scheduled sessions plus the optional retreatment, against 90.0% (27 of 30) in the delayed-treatment group where retreatment was not offered. Sequenced plans lose people between visits even inside a monitored trial. In a clinic, the visits patients miss are the ones nobody booked before they left the room, which is why plan completion behaves like a med spa retention problem rather than a sales problem.

If a plan is going to be sold as one commitment, the commercial structure has to match the clinical one: a course price that reflects the median course, an assessment visit that is a visit rather than a phone call, and a defined position for the touch-up. Clinics that fold sequenced treatment into a recurring commitment usually end up rebuilding their membership pricing around session counts rather than around a flat monthly credit.

What your software has to do to run a plan across sessions

Everything above turns into a short list of system requirements. Stated in the second person, with no vendor attached, a system that can carry a treatment plan has to do the following.

It has to hold a plan as an object rather than as four unrelated appointments: a regimen with a session count, a position number for each session, and the date of the previous session visible at the moment the next one is booked. It has to support different interval floors for different areas of the same product, since Sculptra alone carries three to four weeks for nasolabial folds and four weeks for the cheek region. It has to keep a running cumulative total of product delivered in the regimen, because these ceilings are cumulative rather than per visit. It has to let an assessment visit exist as its own appointment type, since the Sculptra label makes assessment the gate to the next session. And it has to carry the touch-up as part of the plan rather than as a rebooking.

Two constraints are not calendar constraints and are frequently missed. A labeled use window, like the thirty minutes after preparation for diluted Radiesse, constrains how appointments are stacked in a room. A labeled training requirement, like the indication-specific program required for the decollete, constrains which staff member the booking engine may offer, independently of whether that person is free. Both belong in the eligibility logic of your booking system rather than in a note taped to the fridge.

The table below is a chart-note field spec for an injectable session in a plan. It is our recommendation, not a citation of a legal standard. We found no published federal rule prescribing chart-note content for a medical spa, read on 19 August 2026. 21 CFR 50.1, current as of 1 August 2026, scopes Part 50 to "all clinical investigations regulated by the Food and Drug Administration," which is research rather than routine practice, and medical-record content requirements are set state by state by medical and nursing boards. Check your own state's rules against this list rather than treating it as the rule.

Two fields on that list get skipped most often. The cumulative total gets skipped because it is the only one that cannot be filled in from what is in front of you today. The assessment outcome gets skipped when sessions two, three and four were all booked alongside session one, which produces a chart showing a schedule being executed rather than a patient being evaluated. Whatever client record you keep, that second distinction is the one an inspector or a plaintiff’s expert looks for first.

How to rebuild one plan on your own books this month

Pick the single plan you sell most, and run it through five steps.

1. Pull the current label, not a rep's deck and not a summary. For devices, search the PMA number in FDA's premarket approval database and read the most recent supplement's labeling. Sculptra's is P030050/S039, Radiesse's is P050052/S162, Voluma's is P110033. For toxins, read the DailyMed SPL and note its version number and effective date.

2. Write down, in the label's own words, the session count, the interval, the per-session cap and the cumulative cap. If one of them is absent, write "not stated in the Directions for Use" rather than filling the gap from habit.

3. Separate instructions from study design. If a cadence appears only in the clinical studies section, it describes what a trial did, and your marketing has to describe it the same way.

4. Compare your package price to the median course rather than to the first appointment. Voluma's own document puts the median course at 6.6 mL against a 4.8 mL median first treatment, and the gap between those two numbers is the shape of the problem.

5. Open your booking system and try to break the plan. Book session two inside the interval floor. Book a decollete session with a staff member who has not completed the indication-specific training. Book a fifth session in a four-session regimen. Whatever the system lets you do without a warning is what will eventually happen on a busy Friday.

If you want the same exercise run against your own configuration, we do it live in a walkthrough using your top three plans.

Frequently asked questions

How many Sculptra sessions does a patient need and how far apart?

Sculptra's current Instructions for Use, approved under PMA supplement P030050/S039 on 25 April 2023, limits use to "a single regimen of up to four sequential sessions each spaced three to four-weeks apart." The interval differs by area. For nasolabial folds the label says to re-evaluate no sooner than three to four weeks and to keep a minimum of three to four weeks before a possible next session. For the cheek region it says four weeks in both places. The older three-week figure comes from the 2009 labeling, P030050/S002, which has been superseded twice.

Can you get Botox and filler in the same appointment?

The labels answer part of that question and decline the rest. Within BOTOX Cosmetic, simultaneous treatment of multiple areas is labeled with its own doses: glabellar plus lateral canthal simultaneously is a total of 44 Units, and all three upper-face areas at once is 64 Units. Across a toxin and a filler, these documents do not supply a combined protocol. Sculptra's label states that safety and effectiveness of injecting it at anatomic sites that have had other dermal filler injections have not been evaluated. Same-day combination is a clinical judgment your notes should record, not something a label authorises.

Should a filler touch-up be included in the price or billed separately?

Decide it from how much product a course actually consumes. The Juvederm Voluma XC Directions for Use of 2013 reports that a touch-up treatment "was performed for 82% (195/238) of subjects," that the median total volume to optimal correction was 6.6 mL, and that the median volume at the initial treatment was only 4.8 mL, with a 1.9 mL median touch-up. A price quoted from the first appointment describes about 1.8 mL less product than the median subject received. Whether you include the touch-up or bill it, price the plan against the course.

How long should you wait between laser and filler?

The two biostimulator labels flag the interaction and do not quantify it. Sculptra and Radiesse both warn, in near-identical wording, that if laser treatment, chemical peeling or any other procedure based on active dermal response is considered after treatment, there is a possible risk of eliciting an inflammatory reaction at the implant site, and that the same applies if the implant is administered before the skin has healed completely after such a procedure. Neither label states a number of days in the physician Instructions for Use we read on 19 August 2026. Any interval your clinic uses is a clinical decision, and it should be written into your protocol and your chart notes rather than assumed.

Do the different neurotoxins have the same retreatment interval?

Five of the six use near-identical directive language and one does not. Dysport, XEOMIN, JEUVEAU, DAXXIFY and LETYBO each instruct that the product be administered no more frequently than every three months. BOTOX Cosmetic's label, SPL version 54 effective 18 October 2024, does not instruct. It states that the safety and effectiveness of dosing more frequently than every three months have not been clinically evaluated, which is a record of an evidence gap rather than a minimum interval. The practical difference matters when a scheduling rule is written as if all six said the same thing.

Does each session in a plan need its own consent?

We found no published federal standard that resolves this for a medical spa, read on 19 August 2026. 21 CFR 50.1 scopes Part 50 to clinical investigations regulated by the FDA rather than to routine practice, and informed-consent requirements for elective cosmetic treatment are set by state medical and nursing boards and by state case law. Our operational recommendation is that plan-level consent covers the regimen and its expected course, while each session records its own product, dose, area, assessment and any change to the plan. Confirm the split against your own state's rules.

Can a patient switch toxin brands in the middle of a plan?

Treat it as a new product decision rather than a substitution. Every one of the six cosmetic toxin labels states that its units are not interchangeable with other botulinum toxin preparations, so the dose does not carry across. The approved area may not carry across either: BOTOX Cosmetic is the only one of the six with a labeled platysma band indication as of its 10/2024 label, XEOMIN covers three upper-face areas, and Dysport, JEUVEAU, DAXXIFY and LETYBO are labeled for glabellar lines only. Dysport is also indicated in adults less than 65 years of age.

How should a multi-session plan be documented in the chart?

Capture, at every session, the product trade name, the session number, the date of the previous session in the regimen, the area treated, the dose or volume delivered and the cumulative total for the regimen, the reconstitution or dilution used with its preparation time, and the assessment finding that authorised this session. Add the operator and any indication-specific training that applies. Medical-record content rules are set state by state, so treat that list as a starting spec and check it against your own board's requirements.